Raymond James & Associates Nuvation Bio Inc. Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$1.26 - $2.1 $3,780 - $6,300	-3,000 Reduced 16.94%	14,710 $19,000
Q2 2023 Jul 25, 2023	SELL	$1.56 - $1.84 $6,084 - $7,176	-3,900 Reduced 18.05%	17,710 $31,000
Q1 2023 Apr 14, 2023	BUY	$1.6 - $2.48 $960 - $1,488	600 Added 2.86%	21,610 $35,000
Q4 2022 Feb 08, 2023	SELL	$1.68 - $2.5 $588 - $875	-350 Reduced 1.64%	21,010 $40,000
Q2 2022 Aug 12, 2022	BUY	$3.24 - $5.85 $17,172 - $31,004	5,300 Added 33.0%	21,360 $69,000
Q1 2022 May 11, 2022	BUY	$4.6 - $8.83 $16,560 - $31,788	3,600 Added 28.89%	16,060 $84,000
Q4 2021 Feb 08, 2022	BUY	$7.75 - $10.05 $7,750 - $10,050	1,000 Added 8.73%	12,460 $106,000
Q3 2021 Nov 02, 2021	BUY	$7.78 - $10.0 $3,890 - $5,000	500 Added 4.56%	11,460 $114,000
Q2 2021 Aug 11, 2021	BUY	$9.22 - $14.48 $101,051 - $158,700	10,960 New	10,960 $102,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.